Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the ...
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
On Monday, Eli Lilly And Co (NYSE:LLY) announced plans to boost its presence in the U.K., following a collaboration with the ...
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...
On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...
Drugmaker Eli Lilly signed an agreement with the U.K. government to support early-stage life sciences businesses in the country. As part of the collaboration, which was announced Monday at the U.K.'s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback